Tapewire

Nasdaq · USD

ERAS

Erasca, Inc.

Export transactions ↓
Tapewire entity
3796
SEC CIK
0001761918
Parsed reports
127

Last 12 months

Inside the activity.

0 purchase rows · 3 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202601
Feb 202600
Mar 202601
Apr 202601
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
July 20, 2021 Filed Jul 22, 2021 20:10 UTC
Chen BihuaDirector
ConversionSeries A Convertible Preferred Stock · Derivative 4,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-21-013838 · doc1.xml · derivative · entry 3

Chen Bihua · CIK 0001599214 · Director

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 4,000,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F1 · price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F5 · ownership.nature: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 677,600 shares of Common Stock held by the Master Fund, (ii) 3,212,000 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account.

Read SEC document
July 20, 2021 Filed Jul 22, 2021 20:10 UTC
Chen BihuaDirector
PurchaseCommon Stock 950,000 $16.00 $15,200,000.00
Disclosure

SEC source: 0001567619-21-013838 · doc1.xml · nonDerivative · entry 2

Chen Bihua · CIK 0001599214 · Director

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 10,505,553

F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F4 · ownership.nature: Shares reported herein as purchased on July 20, 2021 represent 950,000 shares purchased by the Master Fund.

Read SEC document
July 20, 2021 Filed Jul 22, 2021 20:10 UTC
Chen BihuaDirector
ConversionCommon Stock 9,555,553 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-21-013838 · doc1.xml · nonDerivative · entry 1

Chen Bihua · CIK 0001599214 · Director

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 9,555,553

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3 · ownership.nature: Represents (i) 1,728,710 shares of Common Stock held by the Master Fund, (ii) 7,716,443 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.